Inclusion Criteria:

          -  Age ≥18 years

          -  Newly diagnosed and previously untreated patients with histologically or cytologically
             documented NSCLC with resectable (Stage IIA to select [ie, N2] Stage IIIB) disease

          -  World Health Organization (WHO)/ECOG PS of 0 or 1 at enrollment

          -  At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target
             Lesion (TL) at baseline

          -  No prior exposure to immune-mediated therapy including, but not limited to, other
             anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic
             anticancer vaccines

          -  Adequate organ and marrow function

          -  Confirmation of a patient's tumour PD-L1 status

          -  Provision of sufficient tumour biopsy sample for evaluation and confirmation of EGFR
             and ALK status

          -  Planned surgery must comprise lobectomy, sleeve resection, or bilobectomy

        Exclusion Criteria:

          -  History of allogeneic organ transplantation

          -  Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease, diverticulitis, systemic lupus erythematosus, Sarcoidosis
             syndrome, or Wegener syndrome)

          -  History of another primary malignancy

          -  History of active primary immunodeficiency

          -  Active infection including tuberculosis hepatitis B and C, or human immunodeficiency
             virus

          -  Deemed unresectable NSCLC by multidisciplinary evaluation

          -  Patients who have pre-operative radiotherapy treatment as part of their care plan

          -  Patients who have brain metastases or spinal cord compression

          -  Stage IIIB N3 and Stages IIIC, IVA, and IVB NSCLC

          -  Known allergy or hypersensitivity to any of the study drugs or excipients

          -  Existence of more than one primary tumour such as mixed small cell and NSCLC histology

          -  Patients whose planned surgery at enrollment includes any of the following procedures:
             pneumonectomy, segmentectomies, or wedge resections

          -  Patients with a documented test result confirming the presence of EGFRm or ALK
             translocation